Related references
Note: Only part of the references are listed.
Review
Biochemistry & Molecular Biology
Daniela Gabbia et al.
Summary: Hepatocellular carcinoma (HCC) is the second-leading cause of cancer-related death globally, and efforts have been made to find novel biomarkers for predicting patients' survival and treatment outcomes, especially in immunotherapy. The role of tumor mutational burden (TMB), the total number of mutations per coding area of a tumor genome, has been studied to determine whether it could be a reliable biomarker for stratifying HCC patients into subgroups with different responsiveness to immunotherapy or predicting disease progression, particularly in relation to different HCC etiologies. This review summarizes the recent advances in studying TMB and TMB-related biomarkers in HCC, focusing on their feasibility as guides for therapy decisions and predictors of clinical outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Alessandra Scagliola et al.
Summary: The liver is characterized by high levels of protein synthesis. Initiation factors, essential for tumor progression, may be druggable targets. This review explores how the translational machinery of liver cells contributes to liver pathology and the progression of hepatocellular carcinoma (HCC).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Harshad Devarbhavi et al.
Summary: Liver disease causes two million deaths annually, accounting for 4% of all deaths worldwide, with a higher prevalence among men. The main causes of death are complications of cirrhosis and hepatocellular carcinoma, while acute hepatitis contributes to a smaller proportion. The major factors leading to cirrhosis globally are viral hepatitis, alcohol consumption, and non-alcoholic fatty liver disease. Drug-induced liver injury is also becoming a significant cause of acute hepatitis. This updated version of the global burden of liver disease focuses on new information related to alcohol-associated liver disease, non-alcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma. Moreover, it gives attention to liver disease burden in the often overlooked region of Africa.
JOURNAL OF HEPATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Michele Manganelli et al.
Summary: This study assessed the expression of non-coding RNAs TERRA, TERC, and TERT in hepatocellular carcinoma (HCC) and found their dysregulation. The detection of TERRA and TERC in plasma showed potential diagnostic value for HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Adriana Andrade et al.
Summary: This study examined the role of iPLA2 beta in HCC. The results showed that mice with iPLA2 beta deficiency were protected against HCC by inducing cell-cycle arrest.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Hans Dieter Nischalke et al.
Summary: Hepatocellular carcinoma (HCC) is a severe complication of advanced alcoholic liver disease. This study found an association between genetic variation in SAMM50 and HCC in patients with alcoholic liver disease. Although minor variants of SAMM50 were strongly associated with alcoholic HCC, this association was found to be dependent on the presence of the well-known risk variant PNPLA3 148M.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Keerthi Kurma et al.
Summary: The study demonstrates that vevorisertib, an allosteric AKT inhibitor, effectively suppresses tumor progression and improves liver fibrosis in a hepatocellular carcinoma (HCC) rat model. The combination of vevorisertib with sorafenib shows significant reduction in tumor growth compared to the control group. These findings provide a rationale for clinical testing of vevorisertib and highlight the importance of targeting AKT in HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Manabu Okumura et al.
Summary: Inhibition of the HGF/c-Met axis diminishes the effects of fluoropyrimidine, caution must be exercised when using fluoropyrimidine concomitantly with inhibitors of the HGF/c-Met axis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Daniela Gabbia et al.
Summary: Oxidative stress plays a significant role in the progression of non-alcoholic fatty liver disease (NAFLD) to more severe complications including non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). NADPH oxidases (NOXs) are enzymes that produce reactive oxygen species (ROS) and their abundance in liver cells is closely related to inflammation and immune responses. The differential effects of NOX isoforms, such as NOX1, NOX2, and NOX4, on liver disease progression and HCC prognosis require further investigation.
